STOCK TITAN
  1. Home
  2. News
  3. VRTX

Vertex Pharmaceuticals, Inc. - VRTX STOCK NEWS

Welcome to our dedicated news page for Vertex Pharmaceuticals (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vertex Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vertex Pharmaceuticals's position in the market.

News
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced positive results from its Phase 2 study of the NaV1.8 inhibitor VX-548 in treating painful diabetic peripheral neuropathy. The study showed statistically significant and clinically meaningful reduction in pain intensity, with VX-548 being generally well tolerated. Vertex plans to advance VX-548 into pivotal development for diabetic peripheral neuropathic pain and has also initiated a Phase 2 study in patients with painful lumbosacral radiculopathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.23%
Tags
clinical trial
-
News
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) presents data at ASH Annual Meeting demonstrating consistent and durable response to treatment with CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
none
-
News
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (VRTX) and CRISPR Therapeutics (CRSP) announced the FDA approval of CASGEVY™, a CRISPR-based gene-editing therapy, for the treatment of sickle cell disease in patients 12 years and older. This marks the first-ever approval of a CRISPR-based gene-editing therapy in the U.S. and offers a one-time treatment option for approximately 16,000 eligible patients with severe sickle cell disease. The therapy has the potential to eliminate severe vaso-occlusive crises and hospitalizations caused by the disease, providing a functional cure for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.08%
Tags
fda approval
News
Vertex Appoints Nancy Thornberry to its Board of Directors
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) appoints Nancy Thornberry, a veteran in the pharmaceutical and biotech industries, to its Board of Directors. With over 35 years of experience and a remarkable track record, her addition is expected to bring great value to the company as it continues to expand and progress its pipeline of novel and innovative therapies for serious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
management
-
News
Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO® in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
Rhea-AI Summary
Vertex Pharmaceuticals (VRTX) has applied to expand the approved indication for KAFTRIO® in combination with ivacaftor for the treatment of people with cystic fibrosis (CF) ages 2 and above who have a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive based on clinical and/or in vitro data, including the N1303K mutation. If approved, ~2,800 people with CF in the European Union could receive a medicine that treats the underlying cause of their disease for the first time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
none
-
News
European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
Rhea-AI Summary
Vertex Pharmaceuticals (VRTX) receives European Commission approval for label expansion of KAFTRIO for children ages 2 through 5 years old with cystic fibrosis, potentially treating the underlying cause of the disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced the first regulatory authorization of a CRISPR-based gene-editing therapy in the world. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY, a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The therapy is indicated for eligible patients 12 years of age and older. CASGEVY has been authorized for the treatment of patients with recurrent vaso-occlusive crises or TDT, for whom a human leukocyte antigen (HLA) matched related hematopoietic stem cell donor is not available. The safety profile of patients treated with CASGEVY in clinical trials is generally consistent with myeloablative conditioning with busulfan and hematopoietic stem cell transplant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
none
-
News
Vertex Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Vertex Pharmaceuticals reported Q3 2023 product revenue of $2.48 billion, a 6% increase compared to Q3 2022. The company raised its full-year 2023 product revenue guidance to approximately $9.85 billion. The U.S. FDA Advisory Committee meeting for exa-cel in SCD is completed, with a PDUFA date set for December 8, 2023. The pipeline is advancing with Phase 3 data in CF and acute pain expected in early 2024, and Phase 2 data in neuropathic pain expected in late 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
earnings
-
News
Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition
Rhea-AI Summary
Vertex Pharmaceuticals has announced that seven abstracts have been accepted for presentation at the 2023 ASH Annual Meeting and Exposition. This includes two presentations of updated clinical data on exagamglogene autotemcel's potential as a one-time functional cure for SCD and TDT. Five additional abstracts have been accepted, including two on improvements in patients' quality of life after treatment with exa-cel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
conferences
News
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference
Rhea-AI Summary
Vertex Pharmaceuticals announced that data on TRIKAFTA, a treatment for cystic fibrosis, will be presented at the 2023 North American Cystic Fibrosis Conference. The data will highlight long-term clinical benefits and safety profile among CF pediatric populations. Interim analysis showed sustained improvements in CFTR function and respiratory symptoms, with no decline in lung function. TRIKAFTA was generally safe and well tolerated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
conferences
Stock VRTX logo
Vertex Pharmaceuticals, Inc.

Nasdaq:VRTX

VRTX Rankings

#111 Ranked by Market Cap
#1118 Ranked by Stock Gains
N/A Ranked by Dividends

VRTX Stock Data

102.49B
257.56M
0.11%
97.33%
1.54%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About VRTX

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.